WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02269 WUXI BIO

Not Yet Opened 01-13 16:08:13

39.780

+2.200

+5.85%

High40.180	Low37.800	Vol79.03M
Open37.980	D1 Closing37.580	Amplitude6.33%
Mkt Cap164.45B	Tradable Cap164.45B	Total Shares4.13B
T/O3.12B	T/O Rate1.91%	Tradable Shares4.13B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"WUXI BIO","latestPrice":39.78,"timestamp":1768291693005,"preClose":37.58,"halted":0,"volume":79031708,"delay":0,"floatShares":4134000000,"shares":4134000000,"eps":0.9195930801288804,"marketStatus":"Not Yet Opened","change":2.2,"latestTime":"01-13 16:08:13","open":37.98,"high":40.18,"low":37.8,"amount":3118544600,"amplitude":0.063332,"askPrice":39.78,"askSize":7500,"bidPrice":39.76,"bidSize":413000,"shortable":3,"etf":0,"ttmEps":1.1056131860104075,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":37.58,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":1.933859,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.5099,"impliedVolPercentile":0.1951},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2603035576","title":"WuXi Biologics Receives UK MHRA GMP Certification for Ophthalmic Biologic Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603035576","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603035576?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:07","pubTimestamp":1768273658,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. announced that its Drug Product Facility 5  and Drug Product Packaging Center  in Wuxi have received Good Manufacturing Practice  certifications from the UK Medicines and Healthcare products Regulatory Agency  for the commercial manufacturing of an ophthalmic biologic. The certification follows a four-day inspection with no critical findings. WuXi Biologics provides end-to-end manufacturing services for this product, covering both drug substance and drug product. As of the end of 2025, WuXi Biologics has passed 46 regulatory inspections and obtained 136 facility license approvals, maintaining a 100% pass rate for FDA Pre-License Inspections. The company operates 15 GMP-certified drug substance and drug product facilities within its global network.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL6swnST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0979878070.USD","LU0516422440.USD","LU2039709279.SGD","02269","BK1610","LU0819121731.USD","LU1880383366.USD","LU0307460666.USD","BK1589","LU0348735423.USD","LU0516423091.SGD","LU0572944931.SGD","LU0140636845.USD","LU1688375341.USD","LU0456827905.SGD","LU0588546209.SGD","LU0516422952.EUR","LU0326950275.SGD","LU0456846285.SGD","LU0708995583.HKD","LU0856984785.SGD","BK1141","LU0417516738.SGD","LU0417516902.SGD","LU0823426480.USD","IE00B0JY6N72.USD","SG9999002562.SGD","LU0516423174.USD","LU0327786744.USD","LU0348825331.USD","SG9999002463.SGD","LU1242518857.USD","LU1794554557.SGD","LU0823426308.USD","LU0516422366.SGD","BK1521","LU1242518931.SGD","BK1576","LU0181495838.USD","LU0320764599.SGD","LU0359202008.SGD","LU0039217434.USD","LU0043850808.USD","LU0051755006.USD","LU1720050803.USD","LU0359201612.USD","LU3063872942.SGD"],"gpt_icon":0},{"id":"1151630633","title":"Hong Kong Stocks Movement | CRO Concept Stocks Lead Gains with WUXI APPTEC (02359) Forecasting Doubled Net Profit; Sector Poised for \"Davis Double Play\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1151630633","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151630633?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:17","pubTimestamp":1768270672,"startTime":"0","endTime":"0","summary":"CRO concept stocks led the gains in the Hong Kong market. At the time of writing, WUXI APPTEC (02359) was up 8.48% at HKD 120.2; ASYMCHEM (06821) rose 7.4% to HKD 91.4; PHARMARON (03759) increased...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0320764599.SGD","LU0326950275.SGD","LU0516423091.SGD","LU1808992512.USD","LU1997244956.HKD","LU2045819591.USD","LU1979443071.USD","LU2242644610.SGD","LU0043850808.USD","LU0516422366.SGD","LU0588546209.SGD","BK1589","LU0516422440.USD","LU1997245177.USD","BK1191","LU0052750758.USD","BK0216","BK1610","LU1720050803.USD","03759","LU2328871848.SGD","LU0051755006.USD","BK1576","LU0417516738.SGD","LU2495084118.USD","LU0140636845.USD","BK1521","SG9999002463.SGD","LU2488822045.USD","LU0516423174.USD","603259","LU0348735423.USD","LU0516422952.EUR","LU0307460666.USD","LU0856984785.SGD","LU0823426480.USD","LU1242518857.USD","LU0823426308.USD","BK1141","LU0456842615.SGD","LU0456846285.SGD","SG9999002562.SGD","02359","06821","LU3063872942.SGD","LU2125910500.SGD","02269","LU0327786744.USD","LU0456827905.SGD","LU0819121731.USD","LU1794554557.SGD","LU1934453819.USD","LU1969619763.USD","LU1242518931.SGD","LU0979878070.USD","LU0359201612.USD","LU0039217434.USD","LU0417516902.SGD","LU0359202008.SGD","LU0572944931.SGD","LU1688375341.USD","LU1880383366.USD","LU0348825331.USD","BK1583","LU0708995583.HKD","LU2039709279.SGD","LU1046422090.SGD","IE00B0JY6N72.USD","LU1997245094.SGD","03347"],"gpt_icon":0},{"id":"2602592790","title":"Wuxi Biologics (Cayman) Stock Rallies 1.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2602592790","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602592790?lang=en_us&edition=fundamental","pubTime":"2026-01-12 16:33","pubTimestamp":1768206780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 1.4% to 37.58 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 26608.48.This was the stock's seventh consecutive day of gains.Wuxi Biologics  Inc. closed 12% short of its 52-week high of HK$42.60, which the company achieved Oct. 3.Trading volume totaled 54.7 million shares, compared to the 50-day average of 29.8 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","LU0052750758.USD","LU0456827905.SGD","LU0572944931.SGD","LU0516423091.SGD","SG9999002463.SGD","BK1521","LU0359201612.USD","LU2039709279.SGD","LU0456846285.SGD","LU0516422440.USD","LU0326950275.SGD","LU0516423174.USD","LU0417516738.SGD","LU0327786744.USD","LU0051755006.USD","LU0181495838.USD","LU1880383366.USD","LU0320764599.SGD","LU0708995583.HKD","LU0588546209.SGD","LU1688375341.USD","BK1141","LU0307460666.USD","LU0348735423.USD","LU0348825331.USD","BK1610","SG9999002562.SGD","BK1589","LU1242518931.SGD","LU0516422366.SGD","LU1720050803.USD","LU0516422952.EUR","IE00B0JY6N72.USD","02269","LU1242518857.USD","LU0043850808.USD","LU1794554557.SGD","BK1576","LU0039217434.USD","LU0856984785.SGD","LU0140636845.USD","LU3063872942.SGD","LU0823426308.USD","LU0417516902.SGD","LU0819121731.USD","LU0823426480.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"1187399747","title":"WUXI BIO (02269): Total Integrated Projects Reach Record High of 945 in 2025, Bispecific/Multispecific Antibody Revenue More Than Doubles","url":"https://stock-news.laohu8.com/highlight/detail?id=1187399747","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187399747?lang=en_us&edition=fundamental","pubTime":"2026-01-12 15:51","pubTimestamp":1768204291,"startTime":"0","endTime":"0","summary":"Materials from a keynote speech delivered by WUXI BIO (02269) CEO Chen Zhisheng at the 44th J.P. Morgan Healthcare Conference revealed that the group's business maintained rapid growth in 2025. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU0516423091.SGD","LU0516422952.EUR","LU0039217434.USD","LU0417516738.SGD","BK1576","LU0051755006.USD","LU0856984785.SGD","SG9999002562.SGD","LU0327786744.USD","LU0588546209.SGD","LU0823426308.USD","LU0320764599.SGD","LU0516423174.USD","LU0456846285.SGD","IE00B0JY6N72.USD","LU0456827905.SGD","LU0307460666.USD","LU0819121731.USD","LU1880383366.USD","LU2039709279.SGD","LU0417516902.SGD","LU0359202008.SGD","LU3063872942.SGD","BK1141","LU0572944931.SGD","LU0181495838.USD","LU1242518857.USD","LU1242518931.SGD","LU0348825331.USD","LU0348735423.USD","LU0516422440.USD","BK1610","02269","LU0043850808.USD","LU0979878070.USD","LU1794554557.SGD","LU0052750758.USD","BK1589","LU0359201612.USD","LU0823426480.USD","SG9999002463.SGD","LU0708995583.HKD","LU0516422366.SGD","LU0140636845.USD","BK1521","LU0326950275.SGD","LU1688375341.USD"],"gpt_icon":0},{"id":"1166114367","title":"Market Insights: Focus on TSMC Earnings This Week; Commercial Space Emerges as Strongest Theme","url":"https://stock-news.laohu8.com/highlight/detail?id=1166114367","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166114367?lang=en_us&edition=fundamental","pubTime":"2026-01-12 09:15","pubTimestamp":1768180532,"startTime":"0","endTime":"0","summary":"The A-share market is currently exceptionally strong, with the Shanghai Composite Index breaking through the 4100-point level last Friday and trading volume exceeding three trillion yuan, marking a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e2a27470ec0171f279c35a89d51f30dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","BK4532","LU0158827781.USD","LU1803068979.SGD","LU2106854487.HKD","LU0051755006.USD","LU2133065610.SGD","LU0965508806.USD","LU0823426308.USD","IE00BQXX3C00.GBP","IE00BZ199S13.USD","LU1712237335.SGD","LU2271345857.HKD","LU2471134796.USD","LU0359201885.HKD","LU1037948897.HKD","BK4141","LU0198837287.USD","LU0323591593.USD","LU2111349929.HKD","02269","BK4605","LU0264606111.USD","LU2471134879.HKD","LU0889566641.SGD","BK1587","LU0238689110.USD","LU2125154778.USD","LU1242518931.SGD","LU2491050154.USD","LU2023251221.USD","LU1508157978.USD","LU2860962120.EUR","BK4548","LU1934455277.USD","BK4554","LU0143863198.USD","LU0417516902.SGD","LU0823426480.USD","LU1211504680.USD","LU0965509101.SGD","LU1316542783.SGD","LU1989772840.SGD","LU0353189680.USD","LU0878005551.USD","IE00B0JY6N72.USD","LU2663582299.SGD","LU2491050071.SGD","LU0140636845.USD","LU0327786744.USD","LU0572944931.SGD","LU2357125470.USD","LU0289960550.SGD","BK1610","LU0143863784.USD","LU1720050803.USD","LU0965509010.AUD","LU0719512351.SGD","LU2089283258.USD","LU1794554557.SGD","LU2237443622.USD","LU0516423091.SGD","LU2458330169.SGD","IE00B5TLWC47.USD","LU0882747503.HKD","LU1868838027.USD","LU2125154935.USD","LU2360106780.USD","IE00BD6J9T35.USD","LU2249611893.SGD","LU0642271901.SGD","LU1037948541.HKD","LU3063872942.SGD","IE00BQXX3D17.EUR","LU0541502299.USD","LU0572939691.SGD","LU0856984785.SGD","LU1623119135.USD","LU0348735423.USD","LU0792757196.USD","LU2237443549.SGD","LU2237443978.SGD","LU0516422366.SGD","BK1141","IE00BYQQ9H92.USD","BK4550","LU0823421333.USD","LU1242518857.USD","BK1189","03145","LU0488056044.USD","LU0878004406.USD","SG9999000418.SGD","LU2250418816.HKD","LU0965509283.SGD","LU0124676726.USD","LU2506951792.HKD","LU2023250504.SGD","TSM","LU1989772923.USD","LU0516422440.USD","LU0516422952.EUR","LU2750360641.GBP","LU2458330243.SGD","LU2360108059.USD","LU2211815571.USD","LU0819121731.USD","LU0861579265.USD","LU2471134952.CNY","LU0456827905.SGD","LU1934455863.HKD","BK4585","IE0004086264.USD","LU1868837722.USD","WXXWY","BK4588","LU0039217434.USD","SG9999004220.SGD","IE00BQXX3F31.USD","LU2211814178.USD","IE0004445239.USD","BK4526","LU2039709279.SGD","BK4581","LU1989764664.SGD","LU0316494557.USD","LU0043850808.USD","LU2089284900.SGD","LU2247934214.USD","LU0052750758.USD","LU0516423174.USD","LU0823414478.USD","LU0353189763.USD","LU0359202008.SGD","LU0979878070.USD","LU1880383366.USD","LU1974910355.USD","LU1267930813.SGD","IE00BKPKM429.USD","LU0384037296.USD","BK1521","LU1934455194.USD","BK4543","LU0094547139.USD","SG9999002463.SGD","LU2491049909.HKD","BK4503","IE00BHPRN162.USD","LU2237443382.USD","IE0004091025.USD","LU2294711713.HKD","BK4602","LU0823414551.USD","LU2063271972.USD","LU1023057109.AUD","BK4533","BK4534","LU2028103732.USD","LU0359201612.USD","LU0456846285.SGD","LU2087625088.SGD","LU2543165471.USD","LU1868837565.USD","LU0181495838.USD","LU0158827948.USD","LU2360032135.SGD","BK4612","IE00BFXG0V08.USD","LU2092937221.SGD","LU1852331112.SGD","LU1688375341.USD","LU1282649067.USD","LU2298321311.HKD","LU2471134523.USD","BK4505","SGXZ81514606.USD","BK4527","LU2054465674.USD","LU0348825331.USD","LU0109392836.USD","LU0417516738.SGD","BK1589","LU0823421416.USD","BK4591","LU0689626769.HKD","BK1219","LU0056508442.USD","LU0082616367.USD","LU2750360997.AUD","SG9999002562.SGD","LU1917777945.USD","LU0708995583.HKD","LU0049112450.USD","LU0175139822.USD","BK4512","LU0572940350.SGD","LU2041044095.USD","LU0326950275.SGD","SGXZ99366536.SGD","LU1282649810.SGD","BK1576","LU0307460666.USD","LU1235295612.USD","LU1989764748.USD","SGXZ51526630.SGD","IE00B3M56506.USD","LU0348723411.USD","LU0320764599.SGD","LU0889565833.HKD","LU0541501648.USD","LU1046422090.SGD"],"gpt_icon":1},{"id":"2602559599","title":"Wuxi Biologics Unveils Scaled Global CRDMO Platform Advancing Biologics Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559599","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602559599?lang=en_us&edition=fundamental","pubTime":"2026-01-11 20:52","pubTimestamp":1768135968,"startTime":"0","endTime":"0","summary":"Wuxi Biologics  Inc. has released a presentation outlining its scaled CRDMO  platform, which supports the global advancement of biologics. The presentation details the company’s comprehensive end-to-end offerings across the biologics lifecycle, including services in monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, antibody drug conjugates, viral vaccines, oncolytic viruses, virus-like particles, recombinant proteins, and antibody fragments. Key highlights include support for over 600 IND submissions globally, 25 commercial programs, and 74 Phase III projects. The company reports maintaining high reliability metrics, with a 98.3% DS success rate and a 99.6% DP success rate, and a 100% success rate in regulatory inspections by the FDA, EMA, and NMPA. Wuxi Biologics emphasizes its flexible service model, enabling global clients to access tailored contract services across research, development, and manufacturing. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL4tjbN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0051755006.USD","LU0516423174.USD","SG9999002463.SGD","LU0327786744.USD","LU0979878070.USD","LU0456827905.SGD","LU0516422440.USD","BK1576","LU1242518857.USD","LU1720050803.USD","BK1589","LU0348825331.USD","LU0348735423.USD","LU0823426480.USD","LU0052750758.USD","LU0320764599.SGD","LU0456846285.SGD","BK1141","LU0588546209.SGD","IE00B0JY6N72.USD","02269","LU0417516902.SGD","LU3063872942.SGD","LU0359202008.SGD","LU0823426308.USD","LU1688375341.USD","LU0039217434.USD","LU0417516738.SGD","LU1794554557.SGD","BK1521","LU0043850808.USD","LU0572944931.SGD","LU1242518931.SGD","LU0140636845.USD","LU0708995583.HKD","SG9999002562.SGD","LU0307460666.USD","LU1880383366.USD","LU0326950275.SGD","LU0516422952.EUR","LU0856984785.SGD","LU0516422366.SGD","LU0819121731.USD","LU0181495838.USD","LU0516423091.SGD","BK1610","LU0359201612.USD"],"gpt_icon":0},{"id":"2602568371","title":"Akari Therapeutics Highlights 2025 Progress and Plans Clinical Transition in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602568371","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602568371?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:00","pubTimestamp":1767967216,"startTime":"0","endTime":"0","summary":"Akari Therapeutics plc announced a business update highlighting progress made in 2025 and outlined its path toward becoming a clinical-stage oncology company in 2026. The company is advancing its proprietary PH1 spliceosome-modulating payload for antibody-drug conjugates , designed to deliver both direct tumor cell cytotoxicity and immune activation. In 2025, Akari established a strategic manufacturing partnership with WuXi Biologics and initiated Chemistry, Manufacturing and Controls  and other pre-filing activities to support clinical readiness. The company plans to start its first-in-human clinical trial as early as the end of 2026. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has demonstrated significant activity and prolonged survival in preclinical studies, both as a single agent and in combination with checkpoint inhibitors. IND enabling studies for AKTX-101 are underway, and Akari is also advancing AKTX-102, an ADC targeting a novel antigen r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL837lln:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU1794554557.SGD","LU0516422440.USD","BK4112","LU0856984785.SGD","LU0417516738.SGD","SG9999014013.SGD","SG9999002562.SGD","LU0572944931.SGD","LU2039709279.SGD","BK4588","LU0327786744.USD","LU3063872942.SGD","LU0326950275.SGD","IE00B3QW5Z07.USD","LU0516423091.SGD","BK4007","LU0051755006.USD","LU0181495838.USD","LU1720050803.USD","LU0043850808.USD","BK1589","SG9999014039.USD","IE00BKPKM429.USD","BK1610","LU1880383366.USD","LU2095319765.USD","AKTX","BK4585","LU0516422952.EUR","BK1576","NDAQ","LU0348735423.USD","LU0588546209.SGD","SG9999014021.USD","LU0039217434.USD","LU2210150020.SGD","LU0417516902.SGD","LU0823426308.USD","LU0823426480.USD","BK4139","LU0359201612.USD","LU0140636845.USD","SG9999002463.SGD","IE00B64PRP62.GBP","LU0456846285.SGD","LU0456827905.SGD","LU0320764599.SGD","02269","LU0348825331.USD"],"gpt_icon":0},{"id":"2602632233","title":"BRIEF-BlackRock's Long Position In WuXi Biologics Decreases To 5.61% On Jan 5 From 6.14% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2602632233","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602632233?lang=en_us&edition=fundamental","pubTime":"2026-01-09 18:33","pubTimestamp":1767954823,"startTime":"0","endTime":"0","summary":"BRIEF-BlackRock's Long Position In WuXi Biologics Decreases To 5.61% On Jan 5 From 6.14% - HKEXJan 9 (Reuters) - HKEX:BLACKROCK'S LONG POSITION IN WUXI BIOLOGICS 2269.HK DECREASES TO 5.61% ON JAN 5 FROM 6.14%Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA03P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU1720050803.USD","LU0307460666.USD","LU0708995583.HKD","LU0516423091.SGD","LU0348825331.USD","LU0819121731.USD","LU0043850808.USD","LU0140636845.USD","BK1141","LU0979878070.USD","BK1589","LU2039709279.SGD","LU0516422440.USD","LU1880383366.USD","LU0327786744.USD","LU0516422952.EUR","LU0348735423.USD","LU1242518931.SGD","LU0359201612.USD","SG9999002562.SGD","BK1521","BK1610","LU0359202008.SGD","LU0181495838.USD","LU0456846285.SGD","LU0051755006.USD","LU0823426480.USD","LU0516422366.SGD","LU3063872942.SGD","LU0320764599.SGD","LU0039217434.USD","LU1688375341.USD","LU0417516902.SGD","LU0456827905.SGD","LU0856984785.SGD","LU1242518857.USD","LU0823426308.USD","BK1576","LU0417516738.SGD","LU1794554557.SGD","SG9999002463.SGD","IE00B0JY6N72.USD","02269","LU0326950275.SGD","LU0588546209.SGD","LU0572944931.SGD","LU0516423174.USD"],"gpt_icon":0},{"id":"2602662329","title":"BlackRock's Long Position in WuXi Biologics  Decreases to 5.61% on Jan 5 From 6.14% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2602662329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602662329?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:27","pubTimestamp":1767950834,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA03P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1576","LU0588546209.SGD","LU0140636845.USD","BK1610","LU0823426480.USD","LU0516422366.SGD","02269","LU0359201612.USD","LU3063872942.SGD","SG9999002463.SGD","LU0417516902.SGD","LU0051755006.USD","LU0819121731.USD","LU0516423091.SGD","LU0516422952.EUR","LU1688375341.USD","LU0348825331.USD","LU1720050803.USD","BK1141","LU0043850808.USD","LU0516423174.USD","LU1242518931.SGD","LU1242518857.USD","LU0039217434.USD","BK1589","LU2039709279.SGD","LU0417516738.SGD","LU0052750758.USD","BK1521","LU0979878070.USD","LU0327786744.USD","LU0359202008.SGD","LU0516422440.USD","LU0856984785.SGD","LU0456827905.SGD","LU0456846285.SGD","LU0348735423.USD","LU1794554557.SGD","SG9999002562.SGD","LU1880383366.USD","LU0572944931.SGD","LU0320764599.SGD","LU0307460666.USD","LU0708995583.HKD","LU0181495838.USD","LU0326950275.SGD","LU0823426308.USD","IE00B0JY6N72.USD"],"gpt_icon":0},{"id":"2602891325","title":"Wuxi Biologics (Cayman) Stock Rises 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2602891325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602891325?lang=en_us&edition=fundamental","pubTime":"2026-01-09 16:33","pubTimestamp":1767947580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 1.7% to 37.06 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.3% to 26231.79.This was the stock's sixth consecutive day of gains.Wuxi Biologics  Inc. closed 13% below its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 36.1 million shares, compared to the 50-day average of 30.0 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU1794554557.SGD","LU0359201612.USD","LU0320764599.SGD","LU0043850808.USD","LU0823426480.USD","BK1610","LU0348825331.USD","LU0051755006.USD","LU0348735423.USD","LU0359202008.SGD","LU0708995583.HKD","LU0823426308.USD","LU0856984785.SGD","LU0572944931.SGD","LU0516422952.EUR","SG9999002562.SGD","02269","LU1242518931.SGD","LU0588546209.SGD","LU0052750758.USD","LU0516423174.USD","LU1242518857.USD","LU1688375341.USD","LU2039709279.SGD","LU0417516738.SGD","LU3063872942.SGD","LU0327786744.USD","LU0140636845.USD","LU0516423091.SGD","LU0417516902.SGD","LU0979878070.USD","LU0516422366.SGD","LU0456846285.SGD","LU0456827905.SGD","LU1880383366.USD","LU0181495838.USD","BK1521","BK1141","BK1589","LU0039217434.USD","SG9999002463.SGD","LU0326950275.SGD","BK1576","LU0307460666.USD","LU0819121731.USD","LU1720050803.USD","LU0516422440.USD"],"gpt_icon":0},{"id":"2601191362","title":"Whitehawk Therapeutics Unveils ADC Pipeline and Platform Innovations in Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2601191362","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601191362?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:33","pubTimestamp":1767879193,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. has released a corporate presentation detailing its differentiated antibody-drug conjugate  platform, which features three ADC assets licensed from WuXi Biologics and novel linker-payload technology from Hangzhou DAC. The company highlights the use of a proprietary topoisomerase 1  inhibitor with an optimized DAR6 configuration, carbon bridge cleavable linker, and Fc-attenuated antibodies to enhance tumor targeting and minimize toxicity. Preclinical data indicate that the Whitehawk ADC platform demonstrates increased potency, improved stability, and a higher safety margin compared to average TOP1 inhibitor ADCs, with 3-10 times greater potency, 5-25 times more stability, and a 2-3 times higher safety margin in animal models. The portfolio includes three main assets: HWK-007 targeting PTK7 for a range of solid tumors, HWK-016 targeting MUC16 with an IND submitted, and HWK-206 targeting SEZ6 in neuroendocrine and CNS tumors, with anticipated clinical developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5lK8XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","BK1141","LU0039217434.USD","SG9999002562.SGD","LU0348825331.USD","LU0708995583.HKD","LU0326950275.SGD","LU0588546209.SGD","SG9999002463.SGD","LU0140636845.USD","LU0456827905.SGD","LU1242518857.USD","LU0348735423.USD","LU1794554557.SGD","LU0052750758.USD","BK1610","LU0043850808.USD","LU1720050803.USD","LU2039709279.SGD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0359201612.USD","LU0516423174.USD","LU1242518931.SGD","BK1521","LU0823426308.USD","BK1589","LU0516422952.EUR","LU1688375341.USD","LU0572944931.SGD","LU0359202008.SGD","LU0417516738.SGD","LU0320764599.SGD","LU3063872942.SGD","LU0181495838.USD","LU0456846285.SGD","WHWK","LU0516422440.USD","LU0819121731.USD","BK1576","LU0307460666.USD","LU0979878070.USD","LU0823426480.USD","LU0516423091.SGD","02269","LU0327786744.USD","LU0516422366.SGD","LU0856984785.SGD","LU0051755006.USD","BK4139"],"gpt_icon":0},{"id":"2601874583","title":"BUZZ-Australia's Canyon Resources rises to nearly 3-month high on Cameroon mine update","url":"https://stock-news.laohu8.com/highlight/detail?id=2601874583","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601874583?lang=en_us&edition=fundamental","pubTime":"2026-01-08 08:02","pubTimestamp":1767830521,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Canyon Resources rises to nearly 3-month high on Cameroon mine update ** Shares of Australia's Canyon Resources CAY.AX rise as much as 11.4% to A$0.245, their highest level since October 15** The bauxite explorer says mining operations at Minim Martap are scheduled to start in February 2026** Minim Martap is co's flagship bauxite mine in Cameroon** CAY stock down 2.8% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y81CP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","BK1141","LU0039217434.USD","SG9999002562.SGD","LU0348825331.USD","LU0708995583.HKD","LU0326950275.SGD","LU0588546209.SGD","SG9999002463.SGD","LU0140636845.USD","LU0456827905.SGD","LU1242518857.USD","LU0348735423.USD","LU1794554557.SGD","LU0052750758.USD","BK1610","LU0043850808.USD","LU1720050803.USD","LU2039709279.SGD","IE00B0JY6N72.USD","LU0417516902.SGD","LU0516423174.USD","LU1242518931.SGD","CAY.AU","BK1521","BK7081","LU0823426308.USD","BK1589","LU0516422952.EUR","LU1688375341.USD","LU0572944931.SGD","LU0359202008.SGD","LU0417516738.SGD","LU0320764599.SGD","LU3063872942.SGD","LU0181495838.USD","LU0456846285.SGD","LU0516422440.USD","LU0819121731.USD","BK1576","LU0307460666.USD","LU0979878070.USD","LU0516423091.SGD","02269","LU0327786744.USD","LU0516422366.SGD","LU0856984785.SGD","LU0051755006.USD","BK7104","LU0359201612.USD"],"gpt_icon":0},{"id":"2601382721","title":"Is WuXi Biologics (SEHK:2269)'s New Procurement Certification a Signal on Supply Chain Resilience?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601382721","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601382721?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:35","pubTimestamp":1767807345,"startTime":"0","endTime":"0","summary":"WuXi Biologics recently achieved ISO 20400 Sustainable Procurement certification, an international standard that embeds sustainability, transparency, and responsibility into its procurement and supplier management practices.\nThis certification highlights how WuXi Biologics has integrated sustainability across its supplier lifecycle, reinforcing supply chain resilience and its broader environmental, social, and governance profile.\nWe will now examine how this new sustainable procurement...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/is-wuxi-biologics-sehk2269s-new-procurement-certification-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/is-wuxi-biologics-sehk2269s-new-procurement-certification-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0516422952.EUR","LU0326950275.SGD","BK1576","LU0359201612.USD","02269","LU0417516902.SGD","LU0708995583.HKD","LU0327786744.USD","LU0819121731.USD","LU0823426480.USD","LU1242518931.SGD","LU0181495838.USD","LU0417516738.SGD","LU0456846285.SGD","LU0456827905.SGD","LU0140636845.USD","LU0823426308.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0051755006.USD","LU1688375341.USD","LU3063872942.SGD","LU0979878070.USD","SG9999002562.SGD","LU0348735423.USD","LU0052750758.USD","LU0307460666.USD","LU1720050803.USD","LU0359202008.SGD","LU1880383366.USD","BK1610","LU0348825331.USD","BK1589","LU0516422440.USD","SG9999002463.SGD","LU0856984785.SGD","LU0320764599.SGD","LU1794554557.SGD","BK1141","LU0516423091.SGD","LU0516423174.USD","BK1521","LU2039709279.SGD","LU0516422366.SGD","LU1242518857.USD","LU0572944931.SGD","LU0588546209.SGD","LU0039217434.USD"],"gpt_icon":0},{"id":"2601025188","title":"BRIEF-Blackrock's Long Position In Wuxi Biologics (Cayman) Increases To 6.14% On Jan 2, HKEX Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2601025188","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601025188?lang=en_us&edition=fundamental","pubTime":"2026-01-07 23:42","pubTimestamp":1767800529,"startTime":"0","endTime":"0","summary":"BRIEF-Blackrock's Long Position In Wuxi Biologics (Cayman) Increases To 6.14% On Jan 2, HKEX ShowsJan 7 (Reuters) - HKEX:BLACKROCK'S LONG POSITION IN WUXI BIOLOGICS (CAYMAN) 2269.HK INCREASES TO 6.14% ON JAN 2 FROM 5.32%Further company coverage: 2269.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y717K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422366.SGD","LU0043850808.USD","LU2039709279.SGD","BK1576","LU0348825331.USD","LU1720050803.USD","SG9999002463.SGD","02269","BK1610","LU0456846285.SGD","LU0572944931.SGD","BK1141","LU0417516738.SGD","LU0516422440.USD","LU0348735423.USD","LU1688375341.USD","SG9999002562.SGD","LU0516423174.USD","LU0708995583.HKD","LU0516422952.EUR","LU0823426308.USD","LU0320764599.SGD","LU0823426480.USD","LU0051755006.USD","LU0516423091.SGD","LU0979878070.USD","LU0307460666.USD","LU0359202008.SGD","LU0140636845.USD","LU0819121731.USD","LU1242518857.USD","LU3063872942.SGD","LU0039217434.USD","LU0327786744.USD","LU1880383366.USD","LU0588546209.SGD","BK1521","LU0856984785.SGD","LU1242518931.SGD","LU0052750758.USD","LU0181495838.USD","LU0417516902.SGD","LU1794554557.SGD","BK1589","LU0456827905.SGD","IE00B0JY6N72.USD","LU0359201612.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2601879129","title":"WuXi Biologics CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879129","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601879129?lang=en_us&edition=fundamental","pubTime":"2026-01-07 17:56","pubTimestamp":1767779795,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. CEO Chris Chen, Ph.D., is scheduled to present the keynote, \"A Scaled CRDMO Platform Delivering Sustainable Growth,\" on Wednesday, January 14, at 8:15 AM PST.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLY1X00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","IE00B0JY6N72.USD","LU0327786744.USD","LU0572944931.SGD","BK1141","BK1610","LU0588546209.SGD","LU0856984785.SGD","LU0307460666.USD","LU1880383366.USD","LU0708995583.HKD","LU0348825331.USD","02269","LU0516422440.USD","LU0052750758.USD","BK1589","LU1242518857.USD","LU0456827905.SGD","SG9999002562.SGD","LU0181495838.USD","LU0516422952.EUR","LU0051755006.USD","LU0348735423.USD","LU0823426308.USD","LU0516423174.USD","LU0819121731.USD","LU0516422366.SGD","LU0039217434.USD","LU0823426480.USD","LU0326950275.SGD","LU0359201612.USD","LU0516423091.SGD","LU0140636845.USD","SG9999002463.SGD","BK1576","LU0320764599.SGD","LU0456846285.SGD","LU0043850808.USD","LU2039709279.SGD","LU0979878070.USD","BK1521","LU0359202008.SGD","LU1242518931.SGD","LU0417516738.SGD","LU1720050803.USD","LU1794554557.SGD","LU1688375341.USD","LU3063872942.SGD"],"gpt_icon":0},{"id":"2601687993","title":"BlackRock's Long Position in WuXi Biologics (Cayman)  Increases to 6.14% on Jan 2 From 5.32% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2601687993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601687993?lang=en_us&edition=fundamental","pubTime":"2026-01-07 17:49","pubTimestamp":1767779361,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y717K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU3063872942.SGD","BK1576","LU0348735423.USD","LU0516422366.SGD","SG9999002562.SGD","LU0140636845.USD","IE00B0JY6N72.USD","LU0856984785.SGD","SG9999002463.SGD","LU1688375341.USD","LU0327786744.USD","LU1242518857.USD","LU0307460666.USD","LU0181495838.USD","LU1242518931.SGD","BK1610","LU0516423091.SGD","LU0417516902.SGD","LU0043850808.USD","BK1589","LU0456846285.SGD","BK1141","LU0979878070.USD","BK1521","LU1794554557.SGD","LU0052750758.USD","LU0348825331.USD","LU0320764599.SGD","LU0588546209.SGD","LU0051755006.USD","LU0417516738.SGD","LU0359202008.SGD","LU0456827905.SGD","02269","LU0572944931.SGD","LU0823426308.USD","LU0516423174.USD","LU0039217434.USD","LU1720050803.USD","LU1880383366.USD","LU0823426480.USD","LU0819121731.USD","LU0326950275.SGD","LU2039709279.SGD","LU0516422440.USD","LU0516422952.EUR","LU0359201612.USD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2601902867","title":"Wuxi Biologics (Cayman) Stock Climbs 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601902867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601902867?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:33","pubTimestamp":1767688380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rallied 1.7% to 34.10 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 26710.45.This was the stock's third consecutive day of gains.Wuxi Biologics  Inc. closed 20% short of its 52-week high of HK$42.60, which the company achieved Oct. 3.Trading volume totaled 29.7 million shares, compared to the 50-day average of 28.9 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU3063872942.SGD","LU0348825331.USD","LU0327786744.USD","LU0856984785.SGD","LU1720050803.USD","LU0456846285.SGD","LU0588546209.SGD","LU0819121731.USD","BK1576","LU0979878070.USD","LU0572944931.SGD","LU0823426308.USD","LU0140636845.USD","LU0516422440.USD","LU0307460666.USD","LU0708995583.HKD","LU0320764599.SGD","LU0417516738.SGD","SG9999002463.SGD","BK1589","LU1880383366.USD","LU1688375341.USD","BK1521","02269","LU0516423091.SGD","LU0359202008.SGD","LU0039217434.USD","LU2039709279.SGD","LU0043850808.USD","LU1242518931.SGD","LU0348735423.USD","LU0326950275.SGD","LU0417516902.SGD","LU0516422366.SGD","LU0359201612.USD","LU0456827905.SGD","LU0516422952.EUR","LU0052750758.USD","LU0516423174.USD","LU0051755006.USD","IE00B0JY6N72.USD","LU0181495838.USD","BK1610","SG9999002562.SGD","LU1794554557.SGD","BK1141","LU1242518857.USD","LU0823426480.USD"],"gpt_icon":0},{"id":"2601000909","title":"Wuxi Biologics (Cayman) Stock Rises 3.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000909","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601000909?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:31","pubTimestamp":1767601860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. advanced 3.0% to 33.52 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26347.24.This was the stock's second consecutive day of gains.Wuxi Biologics  Inc. closed 21% below its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 30.2 million shares, compared to the 50-day average of 28.8 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572944931.SGD","LU0516423174.USD","LU1688375341.USD","LU0320764599.SGD","LU0327786744.USD","LU0140636845.USD","LU1794554557.SGD","LU0348735423.USD","LU0979878070.USD","LU0052750758.USD","LU0708995583.HKD","LU1242518857.USD","LU0516422366.SGD","LU1720050803.USD","LU0588546209.SGD","LU0456827905.SGD","LU0516422440.USD","LU3063872942.SGD","LU0819121731.USD","LU1242518931.SGD","BK1589","02269","LU0359201612.USD","BK1576","SG9999002562.SGD","LU0516422952.EUR","LU0417516738.SGD","BK1610","LU0181495838.USD","LU0051755006.USD","LU0823426480.USD","BK1141","LU0039217434.USD","IE00B0JY6N72.USD","LU0043850808.USD","LU0823426308.USD","LU2039709279.SGD","BK1521","LU0516423091.SGD","LU0417516902.SGD","SG9999002463.SGD","LU0348825331.USD","LU0456846285.SGD","LU1880383366.USD","LU0326950275.SGD","LU0856984785.SGD","LU0359202008.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2601164074","title":"WuXi Biologics Achieves ISO 20400 Certification for Sustainable Procurement","url":"https://stock-news.laohu8.com/highlight/detail?id=2601164074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601164074?lang=en_us&edition=fundamental","pubTime":"2026-01-05 11:57","pubTimestamp":1767585476,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. has announced it has achieved ISO 20400 Sustainable Procurement certification, an international standard for integrating sustainability principles into procurement practices. The company reports embedding sustainability across its supplier lifecycle management, covering due diligence, risk management, engagement, performance review, and termination processes. WuXi Biologics states it has adopted an integrated strategy with measurable Science Based Targets initiative  targets and engages with suppliers to promote sustainability throughout its value chain. The company is also a participant in the United Nations Global Compact and has received several ESG ratings and recognitions, including an MSCI AAA Rating, EcoVadis Platinum Medal, and listings in the Dow Jones Sustainability Indices and other ESG indices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4KhRSw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","IE00B0JY6N72.USD","LU0327786744.USD","LU0572944931.SGD","BK1141","BK1610","LU0588546209.SGD","LU0856984785.SGD","LU0307460666.USD","LU1880383366.USD","LU0708995583.HKD","LU0348825331.USD","02269","LU0516422440.USD","LU0052750758.USD","BK1589","LU1242518857.USD","LU0456827905.SGD","SG9999002562.SGD","LU0181495838.USD","LU0516422952.EUR","LU0051755006.USD","LU0348735423.USD","LU0823426308.USD","LU0516423174.USD","LU0819121731.USD","LU0516422366.SGD","LU0039217434.USD","LU0823426480.USD","LU0326950275.SGD","LU0359201612.USD","LU0516423091.SGD","LU0140636845.USD","SG9999002463.SGD","BK1576","LU0320764599.SGD","LU0456846285.SGD","LU0043850808.USD","LU2039709279.SGD","LU0979878070.USD","BK1521","LU0359202008.SGD","LU1242518931.SGD","LU0417516738.SGD","LU1720050803.USD","LU1794554557.SGD","LU1688375341.USD","LU3063872942.SGD"],"gpt_icon":0},{"id":"2600549010","title":"Wuxi Biologics (Cayman) Stock Advances 3.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2600549010","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600549010?lang=en_us&edition=fundamental","pubTime":"2026-01-02 16:30","pubTimestamp":1767342600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 3.5% to 32.54 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.8% to 26338.47.Wuxi Biologics  Inc. closed 24% short of its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 14.4 million shares, compared to the 50-day average of 28.8 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU0516422440.USD","LU0516422952.EUR","LU0140636845.USD","LU0327786744.USD","LU0572944931.SGD","LU0819121731.USD","BK1610","LU1720050803.USD","LU0456827905.SGD","LU1794554557.SGD","LU0051755006.USD","LU0359201612.USD","LU0456846285.SGD","LU0516423091.SGD","LU0181495838.USD","LU0039217434.USD","LU0823426308.USD","LU1688375341.USD","LU3063872942.SGD","LU0856984785.SGD","LU2039709279.SGD","LU0348825331.USD","LU0348735423.USD","LU0417516738.SGD","BK1589","02269","LU0043850808.USD","LU0516422366.SGD","LU0052750758.USD","LU0516423174.USD","BK1141","SG9999002463.SGD","LU0359202008.SGD","LU0979878070.USD","LU0708995583.HKD","LU1242518857.USD","LU1242518931.SGD","LU1880383366.USD","SG9999002562.SGD","BK1521","LU0326950275.SGD","LU0417516902.SGD","LU0823426480.USD","BK1576","LU0307460666.USD","LU0320764599.SGD","IE00B0JY6N72.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":0.1666},{"period":"1month","weight":0.1882},{"period":"3month","weight":0.1068},{"period":"6month","weight":0.4057},{"period":"1year","weight":1.3538},{"period":"ytd","weight":0.2653}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.062692},{"month":2,"riseRate":0.5,"avgChangeRate":-0.003108},{"month":3,"riseRate":0.625,"avgChangeRate":0.020153},{"month":4,"riseRate":0.375,"avgChangeRate":-0.000625},{"month":5,"riseRate":0.5,"avgChangeRate":0.00166},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"WUXI BIO","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WUXI BIO,02269,WUXI BIO股票,WUXI BIO股票老虎,WUXI BIO股票老虎国际,WUXI BIO行情,WUXI BIO股票行情,WUXI BIO股价,WUXI BIO股市,WUXI BIO股票价格,WUXI BIO股票交易,WUXI BIO股票购买,WUXI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}